AMGN
Amgen Inc.
Price Chart
Latest Quote
$344.68
Current Price| Previous Close | $341.88 |
| Open | $340.82 |
| Day High | $345.98 |
| Day Low | $339.51 |
| Volume | 1,899,352 |
Stock Information
| Quarterly Dividend / Yield | $9.66 / 2.80% |
| Shares Outstanding | 538.48M |
| Total Debt | $54.59B |
| Cash Equivalents | $9.45B |
| Revenue | $35.97B |
| Net Income | $7.01B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $185.60B |
| P/E Ratio | 26.66 |
| EPS (TTM) | $12.93 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 15/42| Debt to Equity | 10.23 |
| Debt to Earnings | 2.92 |
| Current Ratio | 1.26 |
| Quick Ratio | 0.84 |
| Avg Revenue Growth | 7.16% |
| Profit Margin | 12.24% |
| Return on Equity | 69.59% |
| Avg FCF Growth | 6.00% |
| FCF Yield | 5.60% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $344.68 | 1,899,400 |
| 2026-01-30 | $341.88 | 2,522,400 |
| 2026-01-29 | $342.94 | 3,153,100 |
| 2026-01-28 | $342.22 | 2,347,800 |
| 2026-01-27 | $351.32 | 3,269,600 |
| 2026-01-26 | $349.69 | 3,116,100 |
| 2026-01-23 | $344.75 | 2,024,900 |
| 2026-01-22 | $347.07 | 3,025,100 |
| 2026-01-21 | $343.60 | 4,148,600 |
| 2026-01-20 | $331.00 | 2,947,500 |
| 2026-01-16 | $330.41 | 4,033,700 |
| 2026-01-15 | $330.03 | 2,591,900 |
| 2026-01-14 | $328.97 | 1,897,400 |
| 2026-01-13 | $324.30 | 2,382,200 |
| 2026-01-12 | $325.54 | 2,460,600 |
| 2026-01-09 | $326.10 | 2,118,400 |
| 2026-01-08 | $330.11 | 2,799,300 |
| 2026-01-07 | $341.64 | 3,599,200 |
| 2026-01-06 | $330.17 | 2,722,500 |
| 2026-01-05 | $320.72 | 2,268,700 |
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
📰 Latest News
AMD earnings, Netflix-Warner Bros. hearing: What to Watch
Yahoo Finance Video • 2026-02-03T00:00:00ZJim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”
Insider Monkey • 2026-02-03T12:24:06Z
Stocks Mostly Rise Pre-Bell as Investors Await Latest Round of Corporate Earnings
MT Newswires • 2026-02-03T12:16:17Z
Assessing Amgen (AMGN) Valuation After Ending Kyowa Kirin Rocatinlimab Collaboration
Simply Wall St. • 2026-02-03T03:14:36Z
Amgen Stock: Is Wall Street Bullish or Bearish?
Barchart • 2026-02-02T14:00:37Z
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
Pharmaceutical Technology • 2026-02-02T11:59:11Z
Amgen (AMGN) Reports Q4: Everything You Need To Know Ahead Of Earnings
StockStory • 2026-02-02T03:11:09Z
January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week
Yahoo Finance • 2026-02-01T12:47:23ZAmgen Refocuses Pipeline As Rocatinlimab Exit Reshapes Dermatology Outlook
Simply Wall St. • 2026-02-01T10:05:49Z
Kyowa Kirin to regain control of rocatinlimab development, commercialization
TipRanks • 2026-01-31T13:21:03Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $12,858,000,000 | $8,451,000,000 | $6,406,000,000 | $6,454,000,000 |
| Cost Of Revenue | $12,858,000,000 | $8,451,000,000 | $6,406,000,000 | $6,454,000,000 |
| Total Revenue | $33,424,000,000 | $28,190,000,000 | $26,323,000,000 | $25,979,000,000 |
| Operating Revenue | $32,026,000,000 | $26,910,000,000 | $24,801,000,000 | $24,297,000,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $3,155,000,000 | $2,875,000,000 | $1,406,000,000 | $1,197,000,000 |
| Total Expenses | $26,166,000,000 | $20,293,000,000 | $16,757,000,000 | $18,340,000,000 |
| Other Income Expense | $506,000,000 | $2,833,000,000 | $-814,000,000 | $259,000,000 |
| Other Non Operating Income Expenses | $506,000,000 | $2,833,000,000 | $-814,000,000 | $259,000,000 |
| Net Non Operating Interest Income Expense | $-3,155,000,000 | $-2,875,000,000 | $-1,406,000,000 | $-1,197,000,000 |
| Interest Expense Non Operating | $3,155,000,000 | $2,875,000,000 | $1,406,000,000 | $1,197,000,000 |
| Operating Expense | $13,308,000,000 | $11,842,000,000 | $10,351,000,000 | $11,886,000,000 |
| Other Operating Expenses | $248,000,000 | $879,000,000 | $503,000,000 | $194,000,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Net Interest Income | $-3,155,000,000 | $-2,875,000,000 | $-1,406,000,000 | $-1,197,000,000 |
| Normalized Income | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Net Income From Continuing And Discontinued Operation | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Total Operating Income As Reported | $7,258,000,000 | $7,897,000,000 | $9,566,000,000 | $7,639,000,000 |
| Net Income Common Stockholders | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Net Income | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Net Income Including Noncontrolling Interests | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Net Income Continuous Operations | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Pretax Income | $4,609,000,000 | $7,855,000,000 | $7,346,000,000 | $6,701,000,000 |
| Operating Income | $7,258,000,000 | $7,897,000,000 | $9,566,000,000 | $7,639,000,000 |
| Gross Profit | $20,566,000,000 | $19,739,000,000 | $19,917,000,000 | $19,525,000,000 |
| Special Income Charges | - | $0 | $0 | $-1,505,000,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $7.56 | $12.49 | $12.11 | $10.28 |
| Basic EPS | $7.62 | $12.56 | $12.18 | $10.34 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $13,356,000,000 | $14,801,000,000 | $12,169,000,000 | $11,296,000,000 |
| Reconciled Depreciation | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 | $3,398,000,000 |
| EBITDA (Bullshit earnings) | $13,356,000,000 | $14,801,000,000 | $12,169,000,000 | $11,296,000,000 |
| EBIT | $7,764,000,000 | $10,730,000,000 | $8,752,000,000 | $7,898,000,000 |
| Diluted Average Shares | $541,000,000 | $538,000,000 | $541,000,000 | $573,000,000 |
| Basic Average Shares | $537,000,000 | $535,000,000 | $538,000,000 | $570,000,000 |
| Diluted NI Availto Com Stockholders | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Tax Provision | $519,000,000 | $1,138,000,000 | $794,000,000 | $808,000,000 |
| Research And Development | $5,964,000,000 | $4,784,000,000 | $4,434,000,000 | $6,324,000,000 |
| Selling General And Administration | $7,096,000,000 | $6,179,000,000 | $5,414,000,000 | $5,368,000,000 |
| Total Unusual Items | - | $0 | $0 | $-1,505,000,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $0 | $-1,505,000,000 |
| Other Special Charges | - | - | - | $1,505,000,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-40,459,000,000 | $-45,038,000,000 | $-27,948,000,000 | $-23,372,000,000 |
| Total Assets | $91,839,000,000 | $97,154,000,000 | $65,121,000,000 | $61,165,000,000 |
| Total Non Current Assets | $62,809,000,000 | $66,822,000,000 | $42,935,000,000 | $41,780,000,000 |
| Other Non Current Assets | $9,930,000,000 | $9,611,000,000 | $5,899,000,000 | $6,524,000,000 |
| Goodwill And Other Intangible Assets | $46,336,000,000 | $51,270,000,000 | $31,609,000,000 | $30,072,000,000 |
| Other Intangible Assets | $27,699,000,000 | $32,641,000,000 | $16,080,000,000 | $15,182,000,000 |
| Current Assets | $29,030,000,000 | $30,332,000,000 | $22,186,000,000 | $19,385,000,000 |
| Other Current Assets | $419,000,000 | $281,000,000 | $355,000,000 | $200,000,000 |
| Prepaid Assets | $2,139,000,000 | $1,647,000,000 | $1,204,000,000 | $1,223,000,000 |
| Inventory | $6,998,000,000 | $9,518,000,000 | $4,930,000,000 | $4,086,000,000 |
| Receivables | $7,501,000,000 | $7,942,000,000 | $6,392,000,000 | $5,839,000,000 |
| Taxes Receivable | $198,000,000 | $172,000,000 | $129,000,000 | $164,000,000 |
| Accounts Receivable | $6,782,000,000 | $7,268,000,000 | $5,563,000,000 | $4,895,000,000 |
| Cash Cash Equivalents And Short Term Investments | $11,973,000,000 | $10,944,000,000 | $9,305,000,000 | $8,037,000,000 |
| Cash And Cash Equivalents | $11,973,000,000 | $10,944,000,000 | $7,629,000,000 | $7,989,000,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $48,126,000,000 | $53,669,000,000 | $31,316,000,000 | $25,320,000,000 |
| Total Debt | $60,099,000,000 | $64,613,000,000 | $38,945,000,000 | $33,309,000,000 |
| Long Term Debt And Capital Lease Obligation | $56,549,000,000 | $63,170,000,000 | $37,354,000,000 | $33,222,000,000 |
| Long Term Debt | $56,549,000,000 | $63,170,000,000 | $37,354,000,000 | $33,222,000,000 |
| Current Debt And Capital Lease Obligation | $3,550,000,000 | $1,443,000,000 | $1,591,000,000 | $87,000,000 |
| Current Debt | $3,550,000,000 | $1,443,000,000 | $1,591,000,000 | $87,000,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $85,962,000,000 | $90,922,000,000 | $61,460,000,000 | $54,465,000,000 |
| Total Non Current Liabilities Net Minority Interest | $62,863,000,000 | $72,530,000,000 | $45,773,000,000 | $42,281,000,000 |
| Other Non Current Liabilities | $2,349,000,000 | $2,326,000,000 | $2,651,000,000 | $2,465,000,000 |
| Tradeand Other Payables Non Current | $2,349,000,000 | $4,680,000,000 | $5,757,000,000 | $6,594,000,000 |
| Non Current Deferred Liabilities | $1,616,000,000 | $2,354,000,000 | $11,000,000 | - |
| Non Current Deferred Taxes Liabilities | $1,616,000,000 | $2,354,000,000 | $11,000,000 | - |
| Current Liabilities | $23,099,000,000 | $18,392,000,000 | $15,687,000,000 | $12,184,000,000 |
| Payables And Accrued Expenses | $18,220,000,000 | $15,568,000,000 | $12,997,000,000 | $10,474,000,000 |
| Interest Payable | $867,000,000 | $936,000,000 | $470,000,000 | - |
| Payables | $5,769,000,000 | $4,459,000,000 | $3,904,000,000 | $3,150,000,000 |
| Dividends Payable | $1,278,000,000 | $1,205,000,000 | $1,137,000,000 | $1,083,000,000 |
| Total Tax Payable | $2,583,000,000 | $1,664,000,000 | $1,195,000,000 | $701,000,000 |
| Income Tax Payable | $2,583,000,000 | $1,664,000,000 | $1,195,000,000 | $701,000,000 |
| Accounts Payable | $1,908,000,000 | $1,590,000,000 | $1,572,000,000 | $1,366,000,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $5,877,000,000 | $6,232,000,000 | $3,661,000,000 | $6,700,000,000 |
| Total Equity Gross Minority Interest | $5,877,000,000 | $6,232,000,000 | $3,661,000,000 | $6,700,000,000 |
| Stockholders Equity | $5,877,000,000 | $6,232,000,000 | $3,661,000,000 | $6,700,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-66,000,000 | $-289,000,000 | $-231,000,000 | $-796,000,000 |
| Other Equity Adjustments | $308,000,000 | $9,000,000 | $117,000,000 | $48,000,000 |
| Retained Earnings | $-27,590,000,000 | $-26,549,000,000 | $-28,622,000,000 | $-24,600,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $537,000,000 | $535,400,000 | $534,000,000 | $558,300,000 |
| Share Issued | $537,000,000 | $535,400,000 | $534,000,000 | $558,300,000 |
| Tangible Book Value | $-40,459,000,000 | $-45,038,000,000 | $-27,948,000,000 | $-23,372,000,000 |
| Invested Capital | $65,976,000,000 | $70,845,000,000 | $42,606,000,000 | $40,009,000,000 |
| Working Capital | $5,931,000,000 | $11,940,000,000 | $6,499,000,000 | $7,201,000,000 |
| Total Capitalization | $62,426,000,000 | $69,402,000,000 | $41,015,000,000 | $39,922,000,000 |
| Foreign Currency Translation Adjustments | $-374,000,000 | $-298,000,000 | $-348,000,000 | $-844,000,000 |
| Capital Stock | $33,533,000,000 | $33,070,000,000 | $32,514,000,000 | $32,096,000,000 |
| Common Stock | $33,533,000,000 | $33,070,000,000 | $32,514,000,000 | $32,096,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,329,000,000 | $1,381,000,000 | $1,099,000,000 | $1,081,000,000 |
| Current Accrued Expenses | $12,451,000,000 | $11,109,000,000 | $9,093,000,000 | $7,324,000,000 |
| Goodwill | $18,637,000,000 | $18,629,000,000 | $15,529,000,000 | $14,890,000,000 |
| Net PPE | $6,543,000,000 | $5,941,000,000 | $5,427,000,000 | $5,184,000,000 |
| Accumulated Depreciation | $-10,388,000,000 | $-9,808,000,000 | $-9,283,000,000 | $-8,798,000,000 |
| Gross PPE | $16,931,000,000 | $15,749,000,000 | $14,710,000,000 | $13,982,000,000 |
| Construction In Progress | $2,053,000,000 | $1,550,000,000 | $1,213,000,000 | $987,000,000 |
| Other Properties | $4,996,000,000 | $4,813,000,000 | $4,684,000,000 | $4,457,000,000 |
| Machinery Furniture Equipment | $4,733,000,000 | $4,540,000,000 | $4,320,000,000 | $4,231,000,000 |
| Buildings And Improvements | $4,803,000,000 | $4,507,000,000 | $4,201,000,000 | $4,028,000,000 |
| Land And Improvements | $346,000,000 | $339,000,000 | $292,000,000 | $279,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,060,000,000 | $2,778,000,000 | $1,004,000,000 | $1,072,000,000 |
| Work In Process | $4,120,000,000 | $5,747,000,000 | $3,098,000,000 | $2,367,000,000 |
| Raw Materials | $818,000,000 | $993,000,000 | $828,000,000 | $647,000,000 |
| Duefrom Related Parties Current | $521,000,000 | $502,000,000 | $700,000,000 | $780,000,000 |
| Treasury Shares Number | - | $0 | - | - |
| Unrealized Gain Loss | - | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $1,676,000,000 | $48,000,000 |
| Current Provisions | - | - | $548,000,000 | $542,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $10,394,000,000 | $7,359,000,000 | $8,785,000,000 | $8,381,000,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $11,490,000,000 | $8,471,000,000 | $9,721,000,000 | $9,261,000,000 |
| Cash Flow From Continuing Operating Activities | $11,490,000,000 | $8,471,000,000 | $9,721,000,000 | $9,261,000,000 |
| Operating Gains Losses | $149,000,000 | $-1,554,000,000 | $1,585,000,000 | $33,000,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,096,000,000 | $-1,112,000,000 | $-936,000,000 | $-880,000,000 |
| Investing Cash Flow | $-1,046,000,000 | $-26,204,000,000 | $-6,044,000,000 | $733,000,000 |
| Cash Flow From Continuing Investing Activities | $-1,046,000,000 | $-26,204,000,000 | $-6,044,000,000 | $733,000,000 |
| Net Other Investing Changes | $50,000,000 | $225,000,000 | $100,000,000 | $-192,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-200,000,000 | $0 | $-6,360,000,000 | $-4,975,000,000 |
| Financing Cash Flow | $-9,415,000,000 | $21,048,000,000 | $-4,037,000,000 | $-8,271,000,000 |
| Cash Flow From Continuing Financing Activities | $-9,415,000,000 | $21,048,000,000 | $-4,037,000,000 | $-8,271,000,000 |
| Net Other Financing Charges | $-783,000,000 | $-719,000,000 | $-400,000,000 | $-78,000,000 |
| Cash Dividends Paid | $-4,832,000,000 | $-4,556,000,000 | $-4,196,000,000 | $-4,013,000,000 |
| Common Stock Dividend Paid | $-4,832,000,000 | $-4,556,000,000 | $-4,196,000,000 | $-4,013,000,000 |
| Net Common Stock Issuance | $-200,000,000 | $0 | $-6,360,000,000 | $-4,975,000,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-3,600,000,000 | $-1,454,000,000 | $0 | $-4,150,000,000 |
| Issuance Of Debt | $0 | $27,777,000,000 | $6,919,000,000 | $4,945,000,000 |
| End Cash Position | $11,973,000,000 | $10,944,000,000 | $7,629,000,000 | $7,989,000,000 |
| Beginning Cash Position | $10,944,000,000 | $7,629,000,000 | $7,989,000,000 | $6,266,000,000 |
| Changes In Cash | $1,029,000,000 | $3,315,000,000 | $-360,000,000 | $1,723,000,000 |
| Common Stock Payments | $-200,000,000 | $0 | $-6,360,000,000 | $-4,975,000,000 |
| Net Issuance Payments Of Debt | $-3,600,000,000 | $26,323,000,000 | $6,919,000,000 | $795,000,000 |
| Net Long Term Debt Issuance | $-3,600,000,000 | $26,323,000,000 | $6,919,000,000 | $795,000,000 |
| Long Term Debt Payments | $-3,600,000,000 | $-1,454,000,000 | $0 | $-4,150,000,000 |
| Long Term Debt Issuance | $0 | $27,777,000,000 | $6,919,000,000 | $4,945,000,000 |
| Net Investment Purchase And Sale | $0 | $1,672,000,000 | $-1,369,000,000 | $4,334,000,000 |
| Sale Of Investment | $0 | $1,673,000,000 | $1,218,000,000 | $13,234,000,000 |
| Purchase Of Investment | $0 | $-1,000,000 | $-2,587,000,000 | $-8,900,000,000 |
| Net Business Purchase And Sale | $0 | $-26,989,000,000 | $-3,839,000,000 | $-2,529,000,000 |
| Purchase Of Business | $0 | $-26,989,000,000 | $-3,839,000,000 | $-2,529,000,000 |
| Net PPE Purchase And Sale | $-1,096,000,000 | $-1,112,000,000 | $-936,000,000 | $-880,000,000 |
| Purchase Of PPE | $-1,096,000,000 | $-1,112,000,000 | $-936,000,000 | $-880,000,000 |
| Change In Working Capital | $2,365,000,000 | $-484,000,000 | $-733,000,000 | $-1,194,000,000 |
| Change In Other Current Liabilities | $-51,000,000 | $-222,000,000 | $-182,000,000 | $-48,000,000 |
| Change In Other Current Assets | $-652,000,000 | $-564,000,000 | $258,000,000 | $-237,000,000 |
| Change In Payables And Accrued Expense | $95,000,000 | $826,000,000 | $679,000,000 | $-315,000,000 |
| Change In Accrued Expense | $1,286,000,000 | $1,888,000,000 | $943,000,000 | $404,000,000 |
| Change In Payable | $-1,191,000,000 | $-1,062,000,000 | $-264,000,000 | $-719,000,000 |
| Change In Account Payable | $312,000,000 | $-402,000,000 | $154,000,000 | $-69,000,000 |
| Change In Tax Payable | $-1,503,000,000 | $-660,000,000 | $-418,000,000 | $-650,000,000 |
| Change In Income Tax Payable | $-1,503,000,000 | $-660,000,000 | $-418,000,000 | $-650,000,000 |
| Change In Inventory | $2,532,000,000 | $491,000,000 | $-742,000,000 | $-165,000,000 |
| Change In Receivables | $441,000,000 | $-1,015,000,000 | $-746,000,000 | $-429,000,000 |
| Changes In Account Receivables | $441,000,000 | $-1,015,000,000 | $-746,000,000 | $-429,000,000 |
| Other Non Cash Items | $-8,000,000 | $563,000,000 | $-303,000,000 | $1,243,000,000 |
| Stock Based Compensation | $530,000,000 | $431,000,000 | $401,000,000 | $341,000,000 |
| Deferred Tax | $-1,228,000,000 | $-1,273,000,000 | $-1,198,000,000 | $-453,000,000 |
| Deferred Income Tax | $-1,228,000,000 | $-1,273,000,000 | $-1,198,000,000 | $-453,000,000 |
| Depreciation Amortization Depletion | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 | $3,398,000,000 |
| Depreciation And Amortization | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 | $3,398,000,000 |
| Depreciation | $5,592,000,000 | $4,071,000,000 | $3,417,000,000 | $3,398,000,000 |
| Earnings Losses From Equity Investments | $-10,000,000 | $11,000,000 | $891,000,000 | $33,000,000 |
| Gain Loss On Investment Securities | $159,000,000 | $-1,565,000,000 | $127,000,000 | - |
| Gain Loss On Sale Of Business | $0 | $0 | $567,000,000 | $0 |
| Net Income From Continuing Operations | $4,090,000,000 | $6,717,000,000 | $6,552,000,000 | $5,893,000,000 |
| Sale Of Business | - | - | $130,000,000 | $0 |